Severe cutaneous adverse reaction to telaprevir

Area of Science:

• Hepatology
• Dermatology
• Pharmacology

Background:

• Hepatitis C treatment often involves combination therapy.
• Telaprevir, in combination with ribavirin and interferon, was used for Hepatitis C.
• Severe cutaneous adverse events are a known risk with certain antiviral medications.

Observation:

• A 50-year-old woman developed a pruritic papular rash three weeks after initiating telaprevir, ribavirin, and interferon therapy.
• The patient presented with cervical lymphadenopathy, fever, eosinophilia, and elevated transaminases.
• These symptoms were indicative of a severe drug reaction, specifically to telaprevir.

Findings:

• The patient's presentation was consistent with a severe drug eruption.
• High-potency topical steroids were administered, leading to recovery within two weeks.
• Telaprevir is associated with serious skin reactions like DRESS, SJS, and TEN, carrying significant mortality.

Implications:

• Physicians must be vigilant for severe cutaneous reactions during telaprevir therapy.
• Early recognition and prompt treatment with corticosteroids are crucial for managing these potentially fatal events.
• Awareness of telaprevir's dermatologic risks is essential for patient safety in Hepatitis C treatment.